Inversago Pharma
about life™
comeback of CB1
inverse agonists
About Inversago Pharma
Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome (PWS), Type-1 Diabetes (T1D), obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH). Inversago’s technology addresses limits associated with first generation CB1 blockers, allowing the company to exploit their full medical potential.
Discover our Company
Targeting unmet needs for a better living
Inversago believes it has the technology to resolve a decade-old problem related to a clinically-validated, in-depth studied, therapeutic approach: safe and efficient CB1 receptor blockade to address a broad range of medical indications (obesity-related conditions, diabetes, NASH/NAFLD, as well as fibrotic disorders).
Our development plan paves the way for a new generation of CB1 inverse agonists/antagonists, in order to strengthen the endocannabinoid system’s ability to regulate the human body’s homeostasis in a more effficient manner.
